BridgeBio Pharma (BBIO) Advances Late Stage Programs, Is The Valuation Still Pricey?
BridgeBio Pharma (BBIO) just packed several late stage updates into a single stretch of October, including new real world data for Attruby, fresh encaleret results, and regulatory progress for oral infigratinib.
BridgeBio Pharma’s latest clinical updates arrived as the share price moved to US$67.94, with a 1-year total shareholder return of 20.77% contrasting with a 90-day share price decline of 17.6%. This hints at pressure on near-term sentiment, while multi-year total shareholder returns of 180.28% over three years and 40.23% over five years point to earlier optimism that recent pipeline progress may now be testing.
Scan how BridgeBio Pharma's late stage pipeline compares with other hand picked biotechs by checking the 20 high quality undiscovered gems that combine clinical momentum with solid fundamentals.
BridgeBio trades at US$67.94 while the average analyst target sits at US$108.27, and an intrinsic value estimate implies an even wider gap. Where does fair value really land in that spread?
Most Popular Narrative: 172% Overvalued
BridgeBio Pharma's last close of $67.94 sits far above the most followed narrative fair value of $25, which frames the current price as rich before any fresh data or commercial execution is even factored in.
The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight.
Here is why the market is mispricing the structural hurdles for BBIO:
See why 4 investors see BridgeBio Pharma as 172% overvalued.
Result: Fair Value of $25 (OVERVALUED)
Still, stronger than expected real world uptake for Attruby or clearer progress infigratinib against entrenched rivals could quickly challenge this 172% overvaluation story.
Find out about the key risks to this BridgeBio Pharma narrative.
Another View: SWS DCF Model Flips The Story
The user narrative pegs BridgeBio Pharma at a fair value of $25 and frames the stock as heavily overpriced. Our DCF model points in the opposite direction, with a future cash flow value estimate of $294.24 per share that treats the current $67.94 price as deeply discounted. Which framework feels more realistic for you: a market-share heavy commercial fight, or a long runway for cash generation?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BridgeBio Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages on BridgeBio Pharma's value story today. Given there are both flagged risks and clear potential rewards in play, move fast and weigh the full picture for yourself by reviewing the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond BridgeBio Pharma?
If BridgeBio Pharma is on your radar, use this moment to refresh your broader watchlist with fresh ideas that match your risk comfort and income goals.
- Target resilient opportunities that focus on capital protection by scanning companies in the 32 resilient stocks with low risk scores.
- Build a watchlist of cash rich businesses with healthier fundamentals by checking the list of solid balance sheet and fundamentals (25 results).
- Lock in potential income streams while you wait for capital gains by reviewing the 8 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com